Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.52 |
| ▸ | NOS2 | P35228 | 3/20 | 0.52 |
| ▸ | NOS1 | P29475 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | USP8 | P40818 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | NCK1 | P16333 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31167609 | 0.78 | ALDH1A1 (0.41) | NOS3NOS2NOS1KDM4EUSP8 | |
| SCHEMBL1428052 | 0.78 | ALDH1A1 (0.41) | NOS3NOS2NOS1KDM4EUSP8 | |
| SCHEMBL9426003 | 0.77 | USP30 (0.39) | KDM4EUSP8TSHRGAAALDH1A1 | |
| SCHEMBL929272 | 0.77 | KMT2A (0.42) | KDM4EUSP8HTTTSHRRAB9A | |
| SCHEMBL21928126 | 0.76 | NQO1 (0.39) | KDM4EUSP8TSHRGAAALDH1A1 | |
| SCHEMBL28018027 | 0.76 | PIK3CD (0.38) | NOS3NOS2NOS1KDM4EUSP8 | |
| SCHEMBL24417209 | 0.74 | USP8 (0.36) | KDM4EUSP8TSHRGAARAB9A | |
| SCHEMBL913934 | 0.74 | BACE1 (0.39) | NOS3NOS2NOS1KDM4EUSP8 | |
| SCHEMBL22129397 | 0.74 | CHEK1 (0.34) | KDM4EUSP8TSHRLMNAGAA | |
| SCHEMBL559359 | 0.74 | NOS3 (0.52) | NOS3NOS2NOS1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119948025-A | Heterocyclic SIK inhibitors | 辉瑞大药厂 | 2025-05-06 | — | — | CN | disclosed |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-11220508-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11174265-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-20210230163-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-29 | — | — | US | disclosed |
| EP-3848370-A2 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10793574-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| WO-2018075937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018071794-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-9556203-B2 | Conformationally restricted P13K and mTOR inhibitors | PIQUR THERAPEUTICS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556203-B2 | Conformationally restricted P13K and mTOR inhibitors | PIQUR THERAPEUTICS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | TORQUR AG (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | TORQUR AG (CH) | 2016-08-25 | — | — | US | disclosed |
| US-9248187-B2 | Oxadiazole inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| EP-2606045-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220508-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS2 4218/4885NOS1 4483/4885 |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS2 4218/4885NOS1 4483/4885 |
| US-10793574-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS2 4218/4885NOS1 4483/4885 |
| US-20210230163-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS2 4218/4885NOS1 4483/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS2 4218/4885NOS1 4483/4885 |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS2 4218/4885NOS1 4483/4885 |
| US-11174265-B2 | — | TYK2, JAK2, JAK1 | NOS3 3882/4885NOS2 3673/4885NOS1 4226/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS2 4218/4885NOS1 4483/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS2 4218/4885NOS1 4483/4885 |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS2 4218/4885NOS1 4483/4885 |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | MTOR, RICTOR, PIK3R4 | NOS3 2476/4885NOS2 3574/4885NOS1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.